002693 Stock Overview

Hainan Shuangcheng Pharmaceuticals Co., Ltd. More details

002693 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Earnings have declined by 25.9% per year over past 5 years

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Competitors

Dezhan Healthcare

SZSE:000813

CN¥7.4b

Jiuzhitang

SZSE:000989

CN¥6.6b

Hainan Haiyao

SZSE:000566

CN¥6.5b

Hunan Er-Kang Pharmaceutical

SZSE:300267

CN¥6.0b

Price History & Performance

Summary of share price highs, lows and changes for Hainan Shuangcheng Pharmaceuticals
Historical stock prices
Current Share Price	CN¥18.00
52 Week High	CN¥20.20
52 Week Low	CN¥17.57
Beta	0.17
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-5.61%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	002693	CN Pharmaceuticals	CN Market
7D	n/a	-1.9%	-0.6%
1Y	n/a	-5.7%	8.3%

Return vs Industry: Insufficient data to determine how 002693 performed against the CN Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 002693 performed against the CN Market.

Price Volatility

Is 002693's price volatile compared to industry and market?
002693 volatility
002693 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.3%
Market Average Movement	8.7%
10% most volatile stocks in CN Market	12.9%
10% least volatile stocks in CN Market	5.6%

Stable Share Price: 002693's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: Insufficient data to determine 002693's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	474	Jianming Li	www.shuangchengmed.com

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People’s Republic of China.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Fundamentals Summary

How do Hainan Shuangcheng Pharmaceuticals's earnings and revenue compare to its market cap?
002693 fundamental statistics
Market cap	CN¥7.46b
Earnings (TTM)	-CN¥86.96m
Revenue (TTM)	CN¥180.64m

41.3x

P/S Ratio

-85.8x

P/E Ratio

Is 002693 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
002693 income statement (TTM)
Revenue	CN¥180.64m
Cost of Revenue	CN¥79.39m
Gross Profit	CN¥101.25m
Other Expenses	CN¥188.21m
Earnings	-CN¥86.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.21
Gross Margin	56.05%
Net Profit Margin	-48.14%
Debt/Equity Ratio	44.9%

How did 002693 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/29 10:57
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hainan Shuangcheng Pharmaceuticals Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jie Yao	Everbright Securities Co. Ltd.
Yun Li	Guodu Securities Co.